{"slug":"pivot","tag":"pivot","variants":["pivot"],"description":"No description yet","count":3,"kinds":{"company":3},"related":[{"slug":"failure","tag":"failure","shared":1}],"records":[{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","route":"/companies/sana-biotechnology/","tldr":"Sana Biotechnology is a hypoimmune cell-therapy company that suspended its oncology allogeneic CAR-T (SC262) in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T (SG293)."},{"id":"nkarta","kind":"company","name":"Nkarta","route":"/companies/nkarta/","tldr":"CAR-NK company that shelved its oncology programmes after falling response rates and pivoted to autoimmune disease."},{"id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","tldr":"TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4)."}]}